预测晚期宫颈癌新辅助化疗疗效的分子标记物研究进展

新辅助化疗（neoadjuvant chemotherapy，NACT）作为综合治疗的一种方法在宫颈癌中主要用于治疗ⅠB2和ⅡA期的巨块型（肿瘤直径≥4 cm）晚期宫颈癌。大部分学者的研究认为，NACT能缩小肿瘤体积，提高可手术率及手术切除率，同时能降低手术并发症，有效率多高达80%以上，其中9%～18%的患者术后病理证实完全缓解。然而还有部分患者对NACT不敏感，如果对这部分患者仍进行NACT治疗就会延误治疗时机造成不必要的痛苦和浪费。近年国内外的研究者做了大量研究试图寻找出与NACT疗效相关的分子标记物，期望能够在分子水平尽早对患者进行NACT疗效预测，发现那些对NACT不敏感的患者而尽早采用其他综合治疗措施，从而改善患者的预后和生存率。综述与宫颈癌NACT疗效相关的分子标记物的研究现状。

Research on Molecular Marker to Predict the Neoadjuvant Chemotherapy Efficacy in Advanced Cervical Cancer

Neoadjuvant chemotherapy（NACT） as one way of the comprehensive therapy mainly used in the case forstageⅠB2 toⅡA disease. Many researchers believed neoadjuvant chemotherapy before surgical can shrink the tumor volume，improve the operability and resection rate. At the same time， it lows the postoperative complications. And the effectiveness is more than 80% including 9%-18% proved completely relived by pathology.However，NACT may delay the patients treatment who can not respond to it and lead to suffering and waste. In recent years，foreign and domestic investigators are trying to find out some molecular markers and hope to predict the efficacy by certain molecular marker and find out the non-responder as early as possible. It can improve the prognosis and survival rate. This paper will summarize the research on prediction efficacy molecular marker in advanced cervical cancer.